Affordable Access

deepdyve-link
Publisher Website

Assessment of the Physical Compatibility of Eravacycline and Common Parenteral Drugs During Simulated Y-site Administration.

Authors
  • Avery, Lindsay M1
  • Chen, Iris H1
  • Reyes, Sergio1
  • Nicolau, David P2
  • Kuti, Joseph L3
  • 1 Center for Anti-Infective Research and Development, Hartford Hospital, Hartford, CT, USA.
  • 2 Center for Anti-Infective Research and Development, Hartford Hospital, Hartford, CT, USA; Department of Infectious Diseases, Hartford Hospital, Hartford, CT, USA.
  • 3 Center for Anti-Infective Research and Development, Hartford Hospital, Hartford, CT, USA. Electronic address: [email protected]
Type
Published Article
Journal
Clinical therapeutics
Publication Date
Oct 01, 2019
Volume
41
Issue
10
Pages
2162–2170
Identifiers
DOI: 10.1016/j.clinthera.2019.08.005
PMID: 31506218
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

Eravacycline is a broad-spectrum, intravenous fluorocycline antibiotic approved for the treatment of complicated intra-abdominal infections in adults. A 60-minute infusion is recommended for each infused dose. Compatibility data that may allow convenient Y-site administration of eravacycline with other parenteral medications are unavailable. We aimed to determine the physical compatibility of eravacycline with other intravenous medications by simulated Y-site administration. Eravacycline was reconstituted according to published prescribing information and diluted with 0.9% sodium chloride to a concentration of 0.6 mg/mL. Simulated Y-site administration was performed by mixing 5 mL of eravacycline with an equal volume of 51 other intravenous medications, including crystalloid and carbohydrate hydration fluids and 20 antimicrobials. Secondary medications were assessed at the upper range of concentrations considered standard for intravenous infusion. Mixtures underwent visual inspection and turbidity measurement immediately on mixture and at 3 subsequent time points (30, 60, and 120 minutes after admixture), and pH was measured at 60 minutes for comparison with the baseline value of the secondary medication. Eravacycline was physically compatible with 41 parenteral drugs (80%) by simulated Y-site administration. Incompatibility was observed with albumin, amiodarone hydrochloride, ceftaroline fosamil, colistimethate sodium, furosemide, meropenem, meropenem/vaborbactam, micafungin sodium, propofol, and sodium bicarbonate. Eravacycline for injection was physically compatible with most parenteral medications assessed. Pharmacists and nurses should be knowledgeable of the observed incompatibilities with eravacycline to prevent the unintentional mixing of incompatible intravenous medications. Copyright © 2019 Elsevier Inc. All rights reserved.

Report this publication

Statistics

Seen <100 times